Category - Developments

Developments

PharmaJet initiates development of needle-free injection pens for home use

Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...

October 7, 2025

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Developments

Aspire files omnibus patent application with USPTO for drug delivery platform

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology. According to Aspire, the technology is designed to enhance...

October 6, 2025

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Developments

Profusa adds leading CLTI surgeon to customer base

Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen...

October 1, 2025

Developments

Larimar reports positive data from study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered...

September 30, 2025

Developments

Anebulo announces first dose in SAD study of IV selonabant for ACI

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy...

September 26, 2025

Developments

ME secures U.S. patent for lead G-CSF antibody candidate

Me Therapeutics Holdings (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate. According to ME, the...

September 26, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Developments

CIPO grants NOA to Moleculin for patent covering Annamycin

Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with...

September 25, 2025

Category - Developments

Subscribe